RIGL news

Latest 1 stories · newest Aug 4, 2026

RIGL

Rigel Reports Q2 2026 Financial Results and In-Licenses VEPPELLEC

Rigel Pharmaceuticals reported $78.7 million in Q2 2026 revenues and $17.3 million in net income. The company advanced its commercial portfolio by in-licensing the PROTAC vepdegestrant from Arvinas.

Earnings|Offering|M&A Aug 4, 2026 sentiment +0.45 SEC filing ↗

BriefTape provides AI-summarized public SEC filings for informational purposes only. Content does not constitute investment advice. Always verify against source filings at sec.gov. BriefTape is not a registered investment adviser, broker-dealer, or financial advisor.

The same RIGL feed as JSON for your bot or app:

GET https://api.brieftape.com/v1/tickers/RIGL/newsSTART FREE